Skip to main content
. 2020 Dec 21;40(12):BSR20201822. doi: 10.1042/BSR20201822

Figure 1. Prognostic value of the RDW prior to NACRT in patients with rectal cancer.

Figure 1

(A) Five-year overall survival (OS) rates have no statistical difference between the pre-RDWHigh group and pre-RDWLow group (P=0.069). (B) Disease-free survival (DFS) curves by pre-RDW. Five-year survival rates have no statistical difference between the pre-RDWHigh group and pre-RDWLow group (P=0.133); NACRT, neoadjuvant chemoradiation therapy.